About Testosterone Replacement Therapy
Testosterone replacement therapy, also called androgen replacement therapy, is typically used to treat hypogonadism. Testosterone, a hormone produced by the testes, is responsible for the development of secondary sexual characters in men. The levels of testosterone decrease gradually with age, but sometimes this decline is seen even in young men, leading to a condition known as hypogonadism. This can be treated with external supply of testosterone in the form of gels, patches, injectable, or oral drugs.
Technavio’s analysts forecast the global testosterone replacement therapy market is gradually declining and will post a CAGR of (3.35) % during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global testosterone replacement therapy market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs that treat and prevent hypogonadism.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Testosterone Replacement Therapy Market 2016-2020
Technavio recognizes the following companies as the key players in the global testosterone replacement therapy market: AbbVie, Allergan, Eli Lilly, and Endo International.
Other Prominent Vendors in the market are: Acerus Pharmaceuticals, Antares Pharma, Bayer HealthCare Pharmaceuticals, Bedford Labs, Clarus Therapeutics, Ferring Pharmaceuticals, Forendo Pharma, Juniper Pharmaceuticals, Lipocine, MetP Pharma, Mylan, Pfizer, ProStrakan, Repros Therapeutics, Sandoz, TesoRx, and Teva Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “Entry of SARMs will be a key trend for market growth. Testosterone therapies available as injectable or skin delivery formulations are currently used as androgen therapies. However, they are associated with side effects related to fluctuations in testosterone levels. The development and entry of SARMs in the market will serve as a better treatment option for androgen deficiencies. These drugs are available as orally active formulations and target androgen receptors specifically, thus eliciting the desired response in the body.”
According to the report, increase in older population will be a key driver for market growth. Age related lowering of testosterone presents features both primary and secondary hypogonadism. Improved healthcare infrastructure and sophisticated treatment facilities have increased life expectancy of individuals. This has led to an increase in older adult population worldwide.
Further, the report states that generic erosion will be a challenge for the market. The entry of generic drugs in the market results in the decline in the overall market revenue, thus affecting the growth of the market. Though all marketed drugs have not lost their respective patents, generic testosterone formulations are available in the market. The branded versions of the drug costs around $300 – $350 per month and generic versions of testosterone shots can be obtained at as low as $20 per dose. Thus, the generic erosion of drugs acts as a challenge for the growth of the market.
AbbVie, Allergan, Eli Lilly, Endo International, Acerus Pharmaceuticals, Antares Pharma, Bayer HealthCare Pharmaceuticals, Bedford Labs, Clarus Therapeutics, Ferring Pharmaceuticals, Forendo Pharma, Juniper Pharmaceuticals, Lipocine, MetP Pharma, Mylan, Pfizer, ProStrakan, Repros Therapeutics, Sandoz, TesoRx, Teva Pharmaceuticals.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook